Medannex today announced an Innovate UK grant to fund a £313,000 project developing a new treatment for paediatric osteosarcoma. The ‘Transforming Cancer Therapeutics’ award will allow the Scottish biotech company to prepare its first-in-class therapy (MDX-124) for a clinical study in this rare childhood cancer.
For full details please press here.